查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887158

猪疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032）

Porcine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

猪隻疫苗市场成长因素

随着全球对动物健康、食品安全和畜牧生产力的日益重视，猪疫苗市场持续扩张。根据本报告预测，该市场规模预计将在2024年达到11.8亿美元，2025年达到12.3亿美元。此外，受猪病发病率上升和全球猪肉需求成长的推动，预计到2032年，该市场将显着增长至19.3亿美元。北美地区在2024年占了全球市场45.76%的占有率，这反映了该地区成熟的疫苗接种实践、强有力的监管支持以及对人畜共患病预防的广泛认识。

猪疫苗在降低猪的疾病负担方面发挥着至关重要的作用，它们透过刺激免疫反应而不引起疾病。这些疫苗采用源自病毒、细菌、毒素和寄生虫的抗原配製而成，帮助养殖户保护牲畜免受毁灭性传染病的侵害。对动物性蛋白质需求的成长和商业养殖场饲养密度的提高增加了疾病传播的风险，进一步推动了猪隻疫苗的使用。例如，2024年初，欧洲养猪场猪流感的盛行率达到了56.6%，凸显了加强疫苗接种策略以保护牲畜健康和经济稳定的必要性。

市场驱动因素

猪病发生率的上升仍然是市场成长最强劲的驱动因素之一。猪繁殖与呼吸综合症（PRRS）、口蹄疫、猪瘟和猪细小病毒等疾病对猪的生产力构成重大威胁。由于猪繁殖与呼吸综合症（PRRS）对繁殖性能和呼吸系统健康的影响，仅PRRS一项每年就给美国养猪业造成约5.6亿美元的损失。全球猪肉消费量的成长进一步推动了对更健康猪群的需求。预计到2023年，全球猪肉产量将达到1.2467亿吨，这将推动疫苗的普及，以预防疫情爆发并确保食品安全。

市场限制因子

儘管需求不断增长，但由于发展中国家疫苗接种率低，市场面临严峻的挑战。兽医基础设施有限、小农户意识薄弱以及经济限制阻碍了疫苗的广泛接种。根据联合国粮农组织的数据，每年约有20%的反刍动物在低收入地区过早死亡，其中近一半的死亡是由可预防的传染病造成的。这些地区疫苗接种的延迟限制了市场成长，并增加了疾病风险。

市场机会

政府主导的措施为市场扩张提供了巨大的机会。多个国家已启动疫苗接种运动，以对抗猪病并增强猪群的抵抗力。例如，印度的畜牧健康和疾病管制计画将于2024-2025年开展针对25万头猪的经典猪瘟（CSF）疫苗接种运动，这将推动对高品质疫苗的需求。预计到2032年，对疾病预防和宣传计画的投入增加将加速疫苗的普及。

市场挑战

猪繁殖与呼吸综合症病毒（PRRSV）和猪流感病毒（SIV）等病原体的快速基因突变使得开发长期普遍有效的疫苗变得困难。这些不断演变的病毒株迫使生产商不断更新疫苗配方。除了生物学挑战外，严格的监管审批流程也会延迟产品上市并增加研发成本。对于计划进行全球产品扩张的公司而言，应对各地区不同的法规仍然是一项重大挑战。

市场趋势

技术进步，特别是基因型特异性疫苗，正在塑造猪免疫的未来。这些疫苗基于病原体的基因谱设计，能够提供更精准的标靶性和更强的免疫反应。 2024年10月，Seba公司基于PCV2d的疫苗Cirbloc M Hyo获得欧洲批准，该疫苗旨在应对猪群中两种最常见的呼吸道病原体。此类创新能够改善猪群健康，减少经济损失，并将基因型疫苗确立为2032年的关键成长趋势。

区域展望

北美

在严格的监管标准、高猪肉消费量和先进的兽医基础设施的支撑下，预计北美市场将在2024年达到5.4亿美元。美国仍然是主要贡献者，这得益于其积极的研发计划，包括开发针对非洲猪瘟 (ASF) 的新疫苗。

欧洲

欧洲在区域市场规模中排名第二，这主要得益于猪肉产量和疾病发生率的成长。在英国，预计 2024 年猪肉产量将增加 8.9%，凸显了持续采取疾病预防措施的必要性。

亚太地区

亚太地区是成长最快的地区，这主要得益于中国、日本、越南和印度庞大的猪隻存栏量。旨在提高疫苗接种率的国家举措，例如 NADCP 项目，将支持市场在 2032 年前的强劲成长。

拉丁美洲、中东和非洲

由于猪肉消费量的增长和动物健康计划的扩展，预计这些地区将经历缓慢但稳定的增长。预计到 2033 年，墨西哥人均猪肉消费量将达到 22.6 公斤，这将增加对疾病预防措施的需求。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要见解

  • 主要国家和地区猪病概览（2024 年）
  • 主要国家及地区监理现况（2024 年）
  • 猪病疫苗概览
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情的影响全球猪疫苗市场

第五章 全球猪隻疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依产品分类
    • 灭活​​疫苗
    • 减毒活疫苗
    • 重组疫苗
    • 其他
  • 市场分析、洞察与预测 - 依给药途径
    • 口服
    • 注射
  • 市场分析、洞察与预测 - 依销售管道
    • 兽医院
    • 兽医诊所
    • 药局
    • 其他
  • 市场分析、洞察与预测 - 依地区
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美猪疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲猪疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太猪疫苗市场分析洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲猪疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲猪疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南亚非洲
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024 年）
  • 公司简介
    • 礼来动保 (Elanco)
    • 喜普拉 (HIPRA)
    • 勃林格殷格翰国际有限公司 (Boehringer Ingelheim International GmbH)
    • 维克 (Virbac)
    • 默克公司 (Merck & Co., Inc.)
    • 硕腾服务有限公司 (Zoetis Services LLC)
    • 赛华 (Ceva)
    • 新健公司 (NEOGEN CORPORATION)
    • 赫斯特生物科学有限公司 (Hester Biosciences Limited)
Product Code: FBI112834

Growth Factors of porcine vaccines Market

The global porcine vaccines market continues to expand as animal health, food safety, and livestock productivity gain higher priority across the world. According to the report, the market was valued at USD 1.18 billion in 2024, is projected to reach USD 1.23 billion in 2025, and is expected to grow significantly to USD 1.93 billion by 2032, driven by rising disease outbreaks in swine populations and increasing global demand for pork. In 2024, North America accounted for 45.76% of the total market share, reflecting its well-established immunization practices, strong regulatory support, and widespread awareness of zoonotic disease prevention.

Porcine vaccines play an essential role in reducing disease burden in pigs by stimulating immune responses without causing illness. These vaccines are formulated using antigens derived from viruses, bacteria, toxins, or parasites, and help farmers protect herds from devastating infectious diseases. Rising demand for animal protein and increased stocking density in commercial farms elevate the risk of disease transmission, further boosting the adoption of porcine vaccines. For example, in early 2024, swine influenza prevalence in European pig herds reached 56.6%, highlighting the need for enhanced immunization strategies to safeguard livestock health and economic stability.

Market Drivers

The growing incidence of swine diseases remains one of the strongest drivers of market growth. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), foot-and-mouth disease, classical swine fever, and porcine parvovirus are major threats to swine productivity. PRRS alone costs the U.S. pork industry around USD 560 million annually, due to its effects on reproduction and respiratory health. Rising global pork consumption further intensifies the need for healthier herds. In 2023, global pig meat production reached 124.67 million tons, driving greater adoption of vaccines to prevent outbreaks and ensure food safety.

Market Restraints

Despite rising demand, the market faces significant challenges due to low immunization uptake in developing countries. Limited veterinary infrastructure, low awareness among small-scale farmers, and economic constraints impede widespread vaccination. According to FAO data, almost 20% of ruminants in low-income regions die prematurely each year, with nearly half of those deaths resulting from preventable infectious diseases. Slow vaccine adoption in these regions restricts market growth and increases disease risks.

Market Opportunities

Government-led initiatives represent a major opportunity for market expansion. Several countries are launching vaccination campaigns to control swine diseases and improve herd resilience. For example, India's Livestock Health & Disease Control Program initiated a 250,000-pig Classical Swine Fever (CSF) vaccination drive for 2024-25, bolstering demand for high-quality vaccines. Growing investments in disease prevention and educational outreach programs are expected to accelerate adoption through 2032.

Market Challenges

Rapid genetic mutations in pathogens like PRRSV and Swine Influenza Virus (SIV) create difficulties in developing long-lasting and universally effective vaccines. These evolving strains challenge manufacturers to constantly update vaccine formulations. Alongside biological challenges, stringent regulatory approvals further slow product launches and increase development costs. Navigating diverse regional regulations continues to be a significant hurdle for companies planning global product expansion.

Market Trends

Technological advancements, especially genotype-specific vaccines, are shaping the future of porcine immunization. These vaccines are engineered based on pathogen genetic profiles, offering improved targeting and stronger immune responses. In October 2024, Ceva secured European approval for Cirbloc M Hyo, a PCV2d-based vaccine designed to address two of the most prevalent respiratory pathogens in swine. Such innovations enhance herd health and reduce economic losses, establishing genotype vaccines as a key growth trend through 2032.

Regional Outlook

North America

North America recorded a market size of USD 0.54 billion in 2024, driven by strong regulatory standards, high pork consumption, and advanced veterinary infrastructure. The U.S. remains the dominant contributor, supported by active R&D programs, including development of new vaccines for African Swine Fever (ASF).

Europe

Europe forms the second-largest regional market, supported by increasing pork production and rising disease prevalence. In the U.K., pig meat production rose 8.9% in 2024, highlighting the need for consistent disease prevention practices.

Asia Pacific

Asia Pacific is the fastest-growing region, driven by large pig populations in China, Japan, Vietnam, and India. National initiatives such as the NADCP program aim to improve immunization rates, supporting strong market expansion through 2032.

Latin America & Middle East/Africa

These regions are experiencing slower but steady growth due to rising pork consumption and expanding animal health programs. In Mexico, pork consumption is expected to reach 22.6 kg per person by 2033, boosting demand for disease control measures.

Conclusion

The porcine vaccines market is positioned for strong long-term growth, increasing from USD 1.18 billion in 2024 to USD 1.23 billion in 2025, and projected to reach USD 1.93 billion by 2032. With rising disease threats, technological advancements, and global initiatives targeting livestock health, demand for effective porcine vaccines will continue accelerating worldwide.

Segmentation By Product

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Porcine Diseases by Key Countries, By Key Countries/ Region, 2024
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Overview of Vaccination for Porcine Diseases
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Porcine Vaccines Market

5. Global Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Pharmacies & Drug Stores
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Pharmacies & Drug Stores
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Pharmacies & Drug Stores
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Pharmacies & Drug Stores
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Pharmacies & Drug Stores
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Pharmacies & Drug Stores
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Elanco
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. HIPRA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Boehringer Ingelheim International GmbH
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Virbac
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co., Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Zoetis Services LLC
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Ceva
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. NEOGEN CORPORATION
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Hester Biosciences Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 2: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 6: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 7: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 10: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 11: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 14: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 18: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 22: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Porcine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Porcine Vaccines Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Porcine Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Porcine Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 7: North America Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 8: North America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 9: North America Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 10: North America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Porcine Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Porcine Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 15: Europe Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 16: Europe Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 17: Europe Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 18: Europe Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 23: Asia Pacific Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 24: Asia Pacific Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 26: Asia Pacific Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 31: Latin America Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 32: Latin America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 33: Latin America Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 34: Latin America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 39: Middle East & Africa Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 40: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 42: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Porcine Vaccines Market Share (%), By Company, 2024